Switzerland’s biotech and pharmaceutical industry is one of the most important pillars of the local economy in various regions. The past two decades have seen the growth of a globally important pharma cluster, in which international companies such as Celgene and MSD have also taken root. The latest example is the biotechnology company Biogen, which is investing around 1.5 billion Swiss francs in a next-generation biologics manufacturing facility in Luterbach. It is currently one of the biggest construction sites in Switzerland. Using the example of Biogen BAK illustrates how the regional economy benefits from the various economic channels of the Swiss pharmaceutical companies.